

# COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study

Koji Mori<sup>1\*</sup>, Takahiro Mori<sup>1</sup>, Tomohisa Nagata<sup>1</sup>, Hajime Ando<sup>2</sup>, Ayako Hino<sup>3</sup>, Seiichiro Tateishi<sup>4</sup>, Mayumi Tsuji<sup>5</sup>, Keiji Muramatsu<sup>6</sup>, Yoshihisa Fujino<sup>7</sup> for the CORoNa Work Project

<sup>1</sup>Department of Occupational Health Practice and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

<sup>2</sup>Department of Work Systems and Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan

<sup>3</sup>Department of Mental Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

<sup>4</sup>Department of Occupational Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Yahatanishi-ku, Kitakyushu 807-8555, Japan

<sup>5</sup>Department of Environmental Health, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

<sup>6</sup>Department of Public Health, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

<sup>7</sup>Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

\* Corresponding author: Koji Mori, [kmori@med.uoeh-u.ac.jp](mailto:kmori@med.uoeh-u.ac.jp)

Short title: COVID-19 vaccination coverage by company size

Total word count: 3369 (6400 max)

1 **Abstract**

2 **Background:** Vaccination is considered the most effective control measure against COVID-

3 19. Vaccine hesitancy and equitable vaccine allocation are important challenges to

4 disseminating developed vaccines. To promote COVID-19 vaccination coverage, the

5 government of Japan established the workplace vaccination program. However, while it

6 appears that the program was effective in overcoming vaccine hesitancy, the program may have

7 hindered the equitable allocation of vaccines because it mainly focused on employees of large

8 companies. We investigated the relationship between company size and COVID-19 vaccination

9 completion status of employees and the impact of the workplace vaccination program on this

10 relationship.

11 **Methods:** We conducted an internet-based prospective cohort study from December 2020

12 (baseline) to December 2021. The data were collected using a self-administered questionnaire

13 survey. Briefly, 27,036 workers completed the questionnaire at baseline and 18,560 at follow-

14 up. After excluding ineligible respondents, we finally analyzed the data from 15,829

15 participants. At baseline, the participants were asked about the size of the company they worked

16 for, and at follow-up they were asked about the month in which they received their second

17 COVID-19 vaccine dose and the availability of a company-arranged vaccination opportunity.

18 **Results:** In each month throughout the observation period, the odds of having received a

19 second COVID-19 vaccine dose were significantly lower for small-company employees than

20 for large-company employees in the sex- and age-adjusted model. This difference decreased  
21 after adjusting for socioeconomic factors, and there was no significant difference after  
22 adjusting for the availability of a company-arranged vaccination opportunity.

23 **Conclusions:** The workplace vaccination program implemented in Japan to control the  
24 COVID-19 pandemic may have been effective in overcoming vaccine hesitancy in workers;  
25 however, it may have caused an inequitable allocation of vaccines between companies of  
26 different sizes. Because people who worked for small companies were less likely to be  
27 vaccinated, it will be necessary to enhance support of vaccination for this population in the  
28 event of future infectious disease outbreaks.

29

30 **Trial registration:** Not applicable.

31

32 **Keywords:** COVID-19, Vaccine hesitancy, Equitable allocation, Workplace vaccination,

33 Company size, Socioeconomic factors

34

## 35 Introduction

36 Vaccination programs are underway worldwide because vaccination is the most effective  
37 measure to control the coronavirus disease 2019 (COVID-19) pandemic, which was declared  
38 by the World Health Organization (WHO) in March 2020. Since the outbreak of COVID-19 in  
39 China in December 2019 [1], various types of vaccines have been developed in a short period  
40 of time [2]. Some of these are mRNA vaccines, representing a new type of vaccine technology  
41 [3].

42         Disseminating vaccines presents many challenges, among which vaccine hesitancy  
43 and equitable allocation are prominent. Vaccine hesitancy, defined as the “delay in acceptance  
44 or refusal of vaccination despite the availability of vaccination services” is considered a major  
45 public health challenge in infectious disease control because it delays vaccination of the  
46 population and inhibits the acquisition of herd immunity [4]. Various factors, including  
47 socioeconomic [5] and psychological factors [4], have been found to contribute to people’s  
48 vaccine hesitancy. Such factors have also been examined in the context of COVID-19  
49 vaccination [6,7]. The equitable allocation of vaccines is based on maintaining equity in the  
50 order of vaccination according to risk regardless of social status, for example by starting with  
51 healthcare workers and those at higher risk of serious illness [8].

52         In Japan, the majority of the population had some level of initial vaccine hesitancy to  
53 receive a COVID-19 vaccine [9,10]. Nevertheless, by the end of December 2021,

54 approximately 80% of the population had received two vaccine doses [11]. In Japan, COVID-  
55 19 vaccination efforts began on February 17, 2021 using two mRNA vaccines: one from Pfizer  
56 Inc. and one from Moderna Inc. In consideration of equitable vaccine allocation, the  
57 vaccination of healthcare workers was followed by the vaccination of older adults [12].  
58 Thereafter, vaccination progressed through the general population in stages according to age.

59 An aspect of COVID-19 vaccination in Japan has been the availability of vaccination  
60 at workplaces in addition to community settings provided by municipalities and clinics [12].  
61 Compared with other developed countries, the start of the vaccination program was delayed in  
62 Japan. To make up for this delay, the government appointed a minister to be in charge and set  
63 a goal of administering one million vaccinations per day. Part of the vaccination strategy was  
64 to implement the opportunity for workplace vaccination, which was conducted mainly by  
65 occupational health professionals such as occupational physicians and occupational health  
66 nurses. As a result, 9,654,000 people received their second vaccine dose through the workplace  
67 vaccination program, which started on June 21, 2021 [13]. Workplace vaccination, which  
68 provides a convenient vaccination opportunity, may have reduced vaccine hesitancy because  
69 several psychological and social factors can positively influence a person's vaccination  
70 decision.

71 The workplace COVID-19 vaccination program in Japan, however, may have  
72 negatively affected the equitable allocation of vaccine doses. This program primarily targeted

73 large companies, with a minimum of 2,000 doses to be delivered to a single location (i.e., an  
74 expected vaccination coverage of at least 1,000 persons [13]). Thus, there were barriers to its  
75 implementation in small and medium-sized companies. Therefore, company size may have  
76 affected the timing and coverage of employees receiving the second COVID-19 vaccine dose.

77 We hypothesized that while the workplace vaccination program facilitated COVID-19  
78 vaccination, there was a size-dependent difference among companies in the timing of  
79 employees receiving the second vaccine dose and that this difference was influenced by the  
80 availability of a company-arranged vaccination opportunity. In a survey conducted in Japan  
81 during the COVID-19 pandemic, there were differences in the implementation of infection  
82 control measures and the opportunity to work remotely depending on the size of the company  
83 [14,15]. Disparities in occupational health measures, such as workplace environmental and  
84 health measures, have arisen and depend on the size of the company. Such disparities have also  
85 been found in the establishment of COVID-19 countermeasures. Therefore, rather than the  
86 government's workplace vaccination program ensuring vaccine equity, this program may have  
87 increased disparities in infection risk because of differences in the completion of COVID-19  
88 vaccination based on company size.

89 We conducted a prospective cohort study to examine the relationship between  
90 company size and COVID-19 vaccination completion and the impact of the workplace  
91 vaccination program on this relationship, focusing on the period between July and December

92 2021, when the general population in Japan was receiving the second vaccine dose.

93

## 94 **Methods**

### 95 **Study design and participants**

96 This study was a part of the Collaborative Online Research on Novel-coronavirus Work Study  
97 (the CORoNa Work Study) and was conducted using a prospective cohort study design. The  
98 survey was commissioned to the internet survey company Cross Marketing Inc. (Tokyo Japan),  
99 and the data were collected using a self-administered online questionnaire. All participants  
100 gave informed consent, and the study was approved by the ethics committee of the University  
101 of Occupational and Environmental Health, Japan (approval number: R2-079 and R3-006).

102 The baseline survey was conducted from December 22 to 25, 2020. The protocol for  
103 the baseline survey has been previously reported in detail [16]. The participants were aged 20–  
104 65 years and were employed at the time of the baseline survey (N=33,087). Participants were  
105 included using cluster sampling by sex, age, region, and occupation. A total of 27,036  
106 participants were included after excluding ineligible individuals: those for which no data on  
107 company size was available, who worked in the medical or welfare sectors, or who were older  
108 than 65 at the time of the follow-up survey.

109 The follow-up survey was conducted from December 15 to 22, 2021, 1 year after  
110 baseline. A total of 18,560 participants responded to the survey. Among them, respondents were



111 excluded if they were unemployed, over 65 years of age, or employed in the health or welfare  
112 sector and thus eligible for priority vaccination at the time of the follow-up survey. Finally,  
113 15,829 participants were included in the analysis. Figure 1 shows the flow diagram for this  
114 study.

115

#### 116 Second COVID-19 vaccination dose status

117 In the follow-up survey, we asked participants, “In what month did you receive the second  
118 COVID-19 vaccination?” Participants were requested to choose one of 12 options: the months  
119 of February 2021 through December 2021, or “have not received.” We then created a variable  
120 for completion status for each month after July. For example, completion by the end of  
121 September was defined as having received a second COVID-19 vaccine dose in any of the  
122 months from February through September. If a participant received the second vaccine dose in  
123 September, completion by July or August would be coded “no” but completion by September,  
124 October, November, and December would be coded “yes”.

125

#### 126 Company size

127 In the baseline survey, we asked participants, “How many employees are there at your  
128 company?” The participants could choose one of 10 options: 1 person (self-employed) or 2–4,  
129 5–9, 10–29, 30–49, 50–99, 100–499, 500–999, 1000–9999, or 10,000 or more persons. We

130 classified the responses into three categories: those who worked for small (1–49), medium-  
131 sized (50–999), or large (1,000 or more) companies. This classification was made because  
132 under the Industrial Safety and Health Act, the obligation to establish an occupational health  
133 management system differs depending on the size of the worksite [17]. Furthermore, the  
134 government-provided workplace vaccination program was eligible for locations that could  
135 vaccinate at least 1,000 people [13].

136

#### 137 Company-arranged vaccination opportunity

138 In the follow-up survey, we asked participants, “Has your company arranged an opportunity to  
139 receive the COVID-19 vaccine at the workplace, whether or not you took advantage of the  
140 opportunity?” Participants could choose one of three response options: yes, no, or unknown.  
141 We regarded “yes” to indicate that the vaccination opportunity was arranged, and the other  
142 answers to indicate that this was not arranged.

143

#### 144 Assessment of covariates

145 Participant characteristics were collected at baseline. The covariates included socioeconomic  
146 factors, occupation, and industry. Age was classified into five groups: 20–29, 30–39, 40–49,  
147 50–59, and 60–65 years. Annual household income was classified into five categories: <2.00  
148 million Japanese yen (JPY), 2.00–3.99 million JPY, 4.00–5.99 million JPY, 6.00–7.99 million

149 JPY, and 8.00 million JPY or greater. Educational background was classified into three  
150 categories: junior high or high school, vocational school or college, and university or graduate  
151 school. Marital status was classified into three categories: married, divorced or widowed, and  
152 unmarried. Occupation was classified into 10 categories: general employee; manager;  
153 executive manager; public employee, faculty member, or non-profit organization employee;  
154 temporary or contract employee; self-employed; small office/home office; agriculture, forestry,  
155 or fishing; professional occupation (e.g., lawyer, tax accountant); and other occupations.  
156 Participants could choose one of 22 options for their work industry, which was then classified  
157 into nine categories based on the International Standard Industrial Classification of All  
158 Economic Activities: manufacturing, public service, information and communication,  
159 wholesale and retail, food service, education and religion, finance and insurance, construction,  
160 and others.

161

## 162 **Statistical analysis**

163 The odds ratios (ORs) for the association between company size and completion of the second  
164 COVID-19 vaccine dose were estimated using a multilevel logistic model nested in the  
165 prefecture of residence to account for regional variability. The multivariate model was adjusted  
166 for sex and age (Model 1) and additionally adjusted for annual household income, educational  
167 background, marital status, occupation, and industry (Model 2). Finally, the model was adjusted

168 for company-arranged vaccination opportunity (Model 3).

169 A *p*-value of less than 0.05 was considered statistically significant. All analyses were  
170 conducted using Stata (Stata Statistical Software: Release 16; StataCorp LLC, College Station,  
171 TX, USA).

172

## 173 Results

174 Table 1 shows the participant characteristics by company size. Of the 15,829 participants, 4,272  
175 (27%) worked for a large company, 5,117 (32%) for a medium-sized company, and 6,440 (41%)  
176 for a small company. As the company size increased, the percentage of participants with a high  
177 annual household income and a high educational background level increased. Furthermore, as  
178 the company size increased, the opportunity for company-arranged vaccination increased: 56%  
179 for large companies, 35% for medium-sized companies, and 14% for small companies.

180 <Insert Table 1>

181 Table 2 shows the ORs for the association between company size and completion of  
182 the second COVID-19 dose by month. In the model adjusted only for age and sex (Model 1),  
183 participants who worked for a medium-sized company were significantly less likely to  
184 complete the second dose by August (OR=0.87, 95% CI: 0.79–0.94,  $p=0.001$ ) and September  
185 (OR=0.86, 95% CI: 0.78–0.93,  $p<0.001$ ) than those who worked for a large company. For small  
186 companies, the ORs decreased throughout the entire observation period, from July to December.

187 In the model adjusted for the main socioeconomic factors (Model 2), the ORs for medium-  
188 sized and small companies tended to approach 1. For August and September, this tendency  
189 remained, but no significant difference was observed for the medium-sized companies. After  
190 adjusting for company-arranged vaccination opportunity (Model 3), the significant difference  
191 between small and large companies disappeared for the entire period analyzed. However, after  
192 October, participants who worked for medium-sized companies were significantly more likely  
193 to have received the second vaccine dose than those who worked for large companies (OR=1.14,  
194 95% CI: 1.01–1.28,  $p < 0.029$ ). In each month throughout the observation period, those who  
195 had a company-arranged vaccination opportunity were significantly more likely to have  
196 received the second vaccine dose.

197 <Insert Table 2>

198

## 199 Discussion

200 This study showed that employees of smaller companies were less likely to have received a  
201 second COVID-19 vaccine dose. In the months after the start of the workplace vaccination  
202 program, the second dose completion rate of participants who worked for medium-sized  
203 companies was lower than that of those who worked for large companies, but this difference  
204 disappeared later in the observation period. The significant difference in completion rate  
205 between small company employees and large company employees remained throughout the

206 observation period. The difference between large and medium-sized company employees could  
207 mostly be explained by differences in socioeconomic factors. However, the difference between  
208 the small and large company employees could not be explained by those factors alone, although  
209 adjusting for the socioeconomic factors reduced the difference. After adjusting for company-  
210 arranged vaccination opportunity, the difference in employee second dose completion rate  
211 between large and small companies disappeared. Furthermore, medium-size companies had  
212 higher vaccine completion coverage than large companies in the latter half of the observation  
213 period.

214           The presence of vaccine hesitancy owing to a lack of trust in vaccination and other  
215 factors has been a challenge to achieving herd immunity through vaccination. Socioeconomic  
216 factors have been found to affect vaccination intention and uptake of other vaccines, such as  
217 the seasonal influenza vaccine [18] and the H1N1 vaccine [19]. The effects of socioeconomic  
218 factors on vaccination intention for the COVID-19 vaccine have also been examined [6,7].  
219 Studies have generally found a positive association between vaccine uptake and annual income  
220 and educational background, although some studies have shown inverse associations [20, 21].  
221 Several studies have found differences in willingness to vaccinate depending on one's  
222 occupation and industry [22-24]. In the current study, after adjusting for socioeconomic factors,  
223 the difference in vaccination completion rate among employees of medium and large  
224 companies disappeared. After these adjustments, the difference between employees of small

225 and large companies also became smaller. These findings suggest that socioeconomic factors  
226 affect the association between COVID-19 vaccination and company size in Japan.

227 In the present study, it was observed that participants who had a company-arranged  
228 vaccination opportunity were significantly more likely to have received the second vaccine  
229 dose, and after adjusting the model for the presence of a company-arranged vaccination  
230 opportunity, no significant difference in the second dose completion rate was found between  
231 employees of small and large companies for all months. These results suggests that the  
232 government's implementation of the workplace vaccination program had a positive impact on  
233 the vaccination acceptance of employees who worked for companies that participated in the  
234 program. The company-arranged vaccination opportunities may have decreased vaccine  
235 hesitancy and increased vaccination coverage. To evaluate the psychosocial factors influencing  
236 vaccine hesitancy, in 2011, the WHO Strategic Advisory Group of Experts proposed the "3C"  
237 model [4], which stands for "Confidence", "Convenience", and "Complacency." German  
238 researchers subsequently proposed the "5C" model, substituting "Constraints" for  
239 "Convenience" and adding "Calculation" and "Collective responsibility" [25]. Company-  
240 arranged vaccination opportunities are thought to increase people's confidence in a vaccine,  
241 and the availability of the vaccine at or near their workplace increases its convenience. In  
242 addition, social environmental factors, such as social norms and herding effects, have been  
243 suggested to affect one's vaccine intention [26,27]. The workplace vaccination program

244 facilitated employees' vaccination behavior to be shared among coworkers and supervisors,  
245 which may have had a direct impact on the social norms and herding effect. Previous studies  
246 on seasonal influenza vaccination in the U.S. have reported that workplace vaccination  
247 practices and recommendations are associated with higher vaccination coverage [28].

248         The influence of socioeconomic factors and company-arranged vaccination  
249 opportunities on vaccination coverage has implications for the equitable allocation of vaccines.  
250 In the workplace vaccination program, the government invited companies that wished to  
251 implement the program on the premise that at least 1,000 people could be vaccinated at a single  
252 location [13]. Multiple small companies could apply if they could jointly secure more than  
253 1,000 people willing to be vaccinated. However, because it was necessary to arrange venues  
254 and medical personnel for the vaccination event and to coordinate costs, program utilization  
255 may vary greatly depending on company size. In Japan, employers with less than 50 full-time  
256 staff are not obligated to appoint an occupational health physician or health supervisor or to  
257 establish a health committee. This lack of obligation means that workers in small companies  
258 often do not have occupational health services available to them [17]. In addition, during the  
259 COVID-19 pandemic in Japan, there were marked differences among companies of different  
260 sizes in the implementation of remote work and infection control measures [14,15]. The  
261 Japanese government's workplace vaccination program may have contributed to health  
262 disparities. Therefore, the pros and cons of a workplace vaccination program and the methods



263 used to realize it warrant further discussion to ensure a more equitable implementation in future  
264 infectious disease outbreaks.

265 It is unclear why there was significantly higher vaccination completion among  
266 participants who worked for medium-sized companies compared with those who worked for  
267 large companies after October 2021 in the model adjusted for both socioeconomic factors and  
268 company-arranged vaccination opportunity. One possible explanation is that many employees  
269 of large companies were located in offices other than the headquarters and therefore had  
270 difficulty accessing the company-arranged vaccination opportunity. Another possibility is that,  
271 although COVID-19 vaccination was voluntary, medium-sized companies are often in a weaker  
272 business position than larger companies, and therefore they may have been more influenced by  
273 pressure from clients to vaccinate their employees in order to continue doing business.

274 This study had several limitations. First, the survey was conducted via the internet, so  
275 generalizations should be made with caution. However, we attempted to reduce any bias by  
276 using cluster sampling with stratification by sex, region, and job type. Second, the study was  
277 likely affected by recall bias. The earlier vaccination was completed, the more time had elapsed  
278 by the time of the survey, which may have caused recall bias. Third, the timing of the follow-  
279 up survey might have affected the responses to the question of vaccination status in the last  
280 month, December. If a person received their second vaccine dose in the last week of December  
281 (after filling out the follow-up survey), they may have answered “unvaccinated” when asked

282 about their vaccination status in the follow-up survey. However, the impact of this situation  
283 was likely small because second-dose vaccination was nearly complete in both the community  
284 and workplace programs by the end of November, and less than 1% of the respondents received  
285 their second vaccine dose in December.

286

## 287 Conclusion

288 During the period when COVID-19 vaccinations were being administered to the general  
289 population in Japan, the coverage of receiving a second COVID-19 vaccine dose was  
290 significantly lower for those who worked for small companies than for those who worked for  
291 large companies. This difference could mostly be explained by socioeconomic factors and the  
292 availability of a vaccination opportunity arranged by the employer. In the event of future  
293 infectious disease outbreaks, it will be necessary to enhance support of vaccination for the  
294 employees of small companies.

295

## 296 List of Abbreviations

297 COVID-19: coronavirus diseases 2019; mRNA: messenger RNA; WHO: World Health  
298 Organization; JPN: Japanese yen; OR: odds ratio; CI: confidence interval.

299

300

301

## References

- 302 1. Lu R, Zhao X, Li J, Niu P, Yang B, Peihua N, et al. Genomic characterisation and  
303 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor  
304 binding. *Lancet*. 2020;395:565–74. [https://doi.org/10.1016/S0140-6736\(20\)30251-83-16](https://doi.org/10.1016/S0140-6736(20)30251-83-16).
- 305 2. Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against  
306 Coronaviruses: The State of the Art. *Vaccines*. 2020;8:309.  
307 <https://doi.org/10.3390/vaccines8020309>
- 308 3. Jin Y, Hou C, Li Y, Zheng K, Wan C. mRNA Vaccine: How to Meet the Challenge of SARS-  
309 CoV-2. *Front Immunol*. 2022;12:821538. <https://doi.org/10.3389/fimmu.2021.821538>.
- 310 4. MacDonald NE, SAGE Working Group on Vaccine Hesitancy Vaccine. Vaccine hesitancy:  
311 Definition, scope and determinants. *Vaccine*. 2015;33(34):4161-64.  
312 <https://doi.org/10.1016/j.vaccine.2015.04.036>.
- 313 5. Larson JH, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine  
314 hesitancy around vaccines and vaccination from a global perspective: a systematic review  
315 of published literature, 2007-2012. *Vaccine*. 17;32(19):2150-59.  
316 <https://doi.org/10.1016/j.vaccine.2014.01.081>.
- 317 6. Lazarus JV, Ratzan SC, Adam Palayew A et al. A global survey of potential acceptance of  
318 a COVID-19 vaccine. 2021; 27(2):225-228. <https://doi.org/10.1038/s41591-020-1124-9>.
- 319 7. Sallam M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of

320 vaccine acceptance rates. *Vaccines* (Basel) 2021; 9(2):160.

321 <https://doi.org/10.3390/vaccines9020160>.

322 8. National Academies of Sciences, Engineering, and Medicine; Health and Medicine

323 Division; Board on Population Health and Public Health Practice; Board on Health

324 Sciences Policy; Committee on Equitable Allocation of Vaccine for the Novel Coronavirus.

325 Framework for Equitable Allocation of COVID-19 Vaccine. National Academies Press

326 (US); 2020. <https://doi.org/10.17226/25917>

327 9. Okubo R, Yoshioka T, Ohfuji S, Matsuo T, Tabuchi T. COVID-19 Vaccine Hesitancy and

328 Its Associated Factors in Japan. *Vaccines* (Basel) 2021;9(6):662. <https://doi.org/>

329 [10.3390/vaccines9060662](https://doi.org/10.3390/vaccines9060662).

330 10. Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, et al. Gender differences

331 in the determinants of willingness to get the COVID-19 vaccine among the working-age

332 population in Japan. *Hum Vaccin Immunother.* 2021;17(11): 3975-81.

333 <https://doi.org/10.1080/21645515.2021.1947098>.

334 11. Prime Minister's Office of Japan. About inoculation schedule of COVID-19 vaccine [In

335 Japanese]. [https://www.kantei.go.jp/jp/headline/kansensho/vaccine\\_supply.html](https://www.kantei.go.jp/jp/headline/kansensho/vaccine_supply.html). Accessed

336 31 March, 2022.

337 12. Ministry of Health, Labour and Welfare. About inoculation to medical staff etc. [In

338 Japanese]. [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine\\_iryoujuujisha.html](https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_iryoujuujisha.html).

339 Accessed 31 March, 2022.

340 13. Ministry of Health, Labour and Welfare. Notice of inoculation at the workplace [In

341 Japanese]. [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine\\_shokuiki.html](https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_shokuiki.html).

342 Accessed 31 March, 2022.

343 14. Ishimaru T, Nagata M, Hino A, Yamashita S, Tateishi S, Tsuji M. Workplace measures

344 against COVID-19 during the winter third wave in Japan: Company size-based differences.

345 J Occup Health. 2021;63(1):e12224. [Hpps://doi.org/10.1002/1348-9585.12224](https://doi.org/10.1002/1348-9585.12224).

346 15. Sasaki N, Imamura K, Kataoka M, Kuroda R, Tsuno K, Sawada U, et al. COVID-19

347 measurements at the workplace in various industries and company sizes: a 2-month follow-

348 up cohort study of full-time employees in Japan. Environ Occup Health Practice. 2021;3.

349 <https://doi.org/10.1539/eohp.2020-0017-OA>.

350 16. Fujino Y, Ishimaru T, Eguchi H, Tsuji M, Tateishi S, Ogami A, et al. Protocol for a

351 nationwide Internet-based health survey in workers during the COVID-19 pandemic in

352 2020. J UOEH 2021;43(2):217-25. <https://doi.org/10.7888/juoeh.43.217>.

353 17. Mori K. Current Status and Issues for the Role of Occupational Health Physicians in Japan.

354 2018 JMA Journal. 1(1)15-21. <https://doi.org/10.31662/jmaj.2018-0011>

355 18. Schmid P, Rauber D, Betsch C, Lidolt G, Denker M-L. Barriers of Influenza Vaccination

356 Intention and Behavior – A Systematic Review of Influenza Vaccine Hesitancy, 2005 –

357 2016. PLoS One. 2017;12:e0170550. <https://doi.org/10.1371/journal.pone.0170550>.

- 358 19. Gargano LM, Painter JE, Sales JM, Morfaw C, Jones LM, Murray D, et al. Seasonal and  
359 2009 H1N1 influenza vaccine uptake, predictors of vaccination and self-reported barriers  
360 to vaccination among secondary school teachers and staff. *Hum Vaccin*. 2011; 7(1):89–95.  
361 <https://doi.org/10.4161/hv.7.1.13460>.
- 362 20. Hak E, Schönbeck Y, De Melker H, Van Essen GA, Sanders EA. Negative attitude of highly  
363 educated parents and health care workers towards future vaccinations in the Dutch  
364 childhood vaccination program. *Vaccine* 2005; 23 (24): 3103-7. [https://doi.org/](https://doi.org/10.1016/j.vaccine.2005.01.074)  
365 [10.1016/j.vaccine.2005.01.074](https://doi.org/10.1016/j.vaccine.2005.01.074).
- 366 21. Wei F, Mullooly JP, Goodman M, McCarty MC, Hanson AM, Crane B, et al. Identification  
367 and characteristics of vaccine refusers. *BMC Pediatr* 2009; 9: 18. [https://doi: 10.1186/1471-](https://doi.org/10.1186/1471-2431-9-18)  
368 [2431-9-18](https://doi.org/10.1186/1471-2431-9-18).
- 369 22. King WC, Rubinstein M, Reinhart A, Mejia R. COVID-19 vaccine hesitancy January-May  
370 2021 among 18-64 year old US adults by employment and occupation. *Prev Med Rep*.  
371 2021;24:101569. <https://doi.org/10.1016/j.pmedr.2021.101569>.
- 372 23. Wang K, Wong EL, Ho K, Cheung AW, Yau PS, Dong D, et al. Change of willingness to  
373 accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different  
374 waves of local epidemic in Hong Kong, China: Repeated cross-sectional surveys. *Vaccines*  
375 (Basel). 2021;9(1):62. <https://doi.org/10.3390/vaccines9010062>.
- 376 24. Dorman C, Perera A, Condon C, Chau C, Qian J, Kalk K, et al. Factors associated with


- 377 willingness to be vaccinated against COVID-19 in a large convenience sample. J  
378 Community Health. 2021;46(5):1013-19. <https://doi.org/10.1007/s10900-021-00987-0>.
- 379 25. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence:  
380 Development of a measure assessing the 5C psychological antecedents of vaccination.  
381 PLoS One. 2018;13(12):e0208601. <https://doi.org/10.1371/journal.pone.0208601>.
- 382 26. Kang GJ, Culp RK, Abbas KM. Facilitators and barriers of parental attitudes and beliefs  
383 toward school-located influenza vaccination in the United States: Systematic review.  
384 Vaccine 2017;35(16):1987-95. <https://doi.org/10.1016/j.vaccine.2017.03.014>.
- 385 27. Agranov M, Elliott M, Ortoleva P. The importance of Social Norms against Strategic  
386 Effects: The case of Covid-19 vaccine uptake. Econ Lett 2021;206:109979. [https://doi.org/](https://doi.org/10.1016/j.econlet.2021.109979)  
387 [10.1016/j.econlet.2021.109979](https://doi.org/10.1016/j.econlet.2021.109979).
- 388 28. Luz PM, Johnson RE, Brown HE. Workplace availability, risk group and perceived barriers  
389 predictive of 2016-17 influenza vaccine uptake in the United States: A cross-sectional study.  
390 Vaccine. 2017;35(43):5890-5896. <https://doi.org/10.1016/j.vaccine.2017.08.078>.

391

392

393

394



395

396 Figure 1. Flow diagram of the study participants

397



398 **Declarations**

399 **Ethical approval and consent to participate**

400 This study was approved by the ethics committee of the University of Occupational and  
401 Environmental Health, Japan (reference nos. R2-079 and R3-006). Informed consent was  
402 obtained from all participants via the survey website.

403

404 **Consent for publication**

405 Not applicable.

406

407 **Availability of data and material**

408 Data available on request from authors.

409 **Competing interests**

410 The authors declare that they have no competing interests.

411

412 **Funding**

413 The study was supported and partly funded by research grants from the University of  
414 Occupational and Environmental Health, Japan (no grant number), the Japanese Ministry of  
415 Health, Labour and Welfare (H30-josei-ippan-002, H30-roudou-ippan-007, 19JA1004,  
416 20JA1006, 210301-1, and 20HB1004), Anshin Zaidan (no grant number), the Collabo-Health

417 Study Group (no grant number), Hitachi Systems, Ltd. (no grant number), and scholarship  
418 donations from Chugai Pharmaceutical Co., Ltd. (no grant number). The funders were not  
419 involved in the study design, collection, analysis, or interpretation of data, the writing of this  
420 article, or the decision to submit it for publication.

421

#### 422 Authors' contributions

423 KM designed the analysis, analyzed the data, and wrote the manuscript. TM designed the  
424 analysis and reviewed the manuscript. TM created the questionnaire, advised on the study  
425 design and data interpretation, and reviewed the manuscript. HA, AH, ST, MT, and SM  
426 reviewed the manuscript and advised on the data interpretation. YF was chairperson of the  
427 study group, created the questionnaire, advised on the data interpretation, and reviewed the  
428 manuscript.

429

#### 430 Acknowledgments

431 The current members of the CORoNa Work Study, in alphabetical order, are as follows: Dr. Hajime Ando,  
432 Dr. Hisashi Eguchi, Dr. Yoshihisa Fujino (present chairperson of the study group), Dr. Arisa Harada, Dr.  
433 Ayako Hino, Dr. Kazunori Ikegami, Dr. Tomohiro Ishimaru, Dr. Kyoko Kitagawa, Ms. Ning Liu, Dr. Kosuke  
434 Mafune, Dr. Shinya Matsuda, Dr. Ryutaro Matsugaki, Dr. Koji Mori, Dr. Keiji Muramatsu, Dr. Masako  
435 Nagata, Dr. Tomohisa Nagata, Dr. Akira Ogami, Dr. Makoto Okawara, Dr. Rie Tanaka, Dr. Seiichiro Tateishi,

436 Dr. Shinya Matsuda, Dr. Tomohiro Ishimaru, and Dr. Tomohisa Nagata. All members are affiliated with the

437 University of Occupational and Environmental Health, Japan.

438

439 Table 1. Participant characteristics according to company size

	Size of belonging company (Number of employees)		
	Large (1000 or more)	Medium (50-999)	Small (1-49)
Total	4272	5117	6440
Age			
20-29	185 (4.3%)	259 (5.1%)	173 (2.7%)
30-39	611 (14.3%)	764 (14.9%)	769 (11.9%)
40-49	1222 (28.6%)	1601 (31.3%)	1898 (29.5%)
50-59	1755 (41.1%)	1929 (35.7%)	2511 (39.0%)
60-65	499 (11.7%)	664 (13.0%)	1089 (16.9%)
Sex			
Men	2781 (65.1%)	3172 (62.0%)	3785 (58.8%)
Women	1491 (34.9%)	1945 (38.0%)	2665 (41.2%)
Annual household income (million JPY)			
<2	128 (3.0)	226 (4.4%)	660 (10.3%)
≥2 and <4	514 (12.0%)	990 (19.3%)	1594 (24.8%)
≥4 and <6	828 (19.4%)	1316 (25.7%)	1610 (25.0%)
≥6 and <8	997 (23.3%)	1068 (20.9%)	1105 (17.2%)
≥8	1805 (42.3%)	1517 (29.6%)	1471 (22.8%)
Educational background			
Junior high or high school	1018 (23.8%)	1426 (27.9%)	2117 (32.9%)
Vocational school, junior college or technical school	613 (14.4%)	1003 (19.6%)	1575 (24.5%)
University or graduate school	2641 (61.8%)	2688 (52.5%)	2748 (42.7%)
Marital status			
Married	1244 (29.1%)	1704 (33.3%)	2296 (35.7%)
Widowed/divorced	339 (7.9%)	432 (8.4%)	755 (11.7%)
Never married	2689 (62.9%)	2981 (58.3%)	3389 (58.3%)
Occupation			
General employee	2104 (49.3%)	2773 (54.2%)	2423 (37.6%)
Manager	691 (16.2%)	753 (14.7%)	382 (5.9%)
Executive manager	31 (0.7%)	107 (2.1%)	494 (7.7%)
Public employee, faculty member, or non-profit organization employee	806 (18.9%)	606 (11.8%)	354 (5.5%)
Temporary/contract employee	603 (14.1%)	810 (15.8%)	340 (5.3%)
Independent business (commercial and industrial services)	9 (0.2%)	15 (0.3%)	1548 (24.0%)
Small office/home office	3 (0.1%)	3 (0.1%)	270 (4.2%)
Agricultural, forestry, and fishing industries	2 (0.0%)	3 (0.1%)	135 (2.1%)
Professional occupation (lawyer, tax accountant, etc.)	11 (0.3%)	14 (0.3%)	140 (2.2%)
Other occupation	12 (0.3%)	33 (0.6%)	354 (5.5%)
Industry			
Manufacturing	1069 (25.0%)	1179 (23.0%)	755 (11.7%)
Public service	638 (14.9%)	389 (7.6%)	203 (3.2%)
Information and technology	312 (7.3%)	331 (6.5%)	287 (4.5%)
Retail and wholesales	244 (5.7%)	355 (6.9%)	629 (9.8%)
Eating/drinking	110 (2.6%)	182 (3.6%)	513 (8.0%)
Education and religion	275 (6.4%)	417 (8.1%)	507 (7.9%)
Finance	434 (10.2%)	213 (4.2%)	161 (2.5%)
Construction	96 (2.3%)	139 (2.7%)	428 (6.7%)
Other	1064 (25.6%)	1912 (37.4%)	2957 (45.9%)
Vaccination arranged by company			
Yes	2383 (55.8%)	1780 (34.8%)	914 (14.2%)
No	1889 (44.2%)	3337 (65.2%)	5526 (85.8%)
Month of 2nd COVID-19 vaccination			
February-June	161 (3.0%)	205 (4.0%)	197 (3.1%)
July	450 (10.5%)	467 (9.1%)	607 (9.4%)
August	1267 (29.7%)	4354 (26.5%)	1550 (24.1%)
September	941 (22.0%)	1140 (22.3%)	1380 (21.4%)
October	774 (18.1%)	1063 (20.8%)	1212 (18.8%)
November	240 (5.6%)	319 (6.2%)	420 (6.5%)
December	21 (0.5%)	35 (0.7%)	40 (0.6%)
Non-vaccinated	418 (9.8%)	534 (10.4%)	1034 (16.1%)

441 Table 2 Association between company size and completion of the second COVID-19 vaccine dose

Second vaccination		model 1			model 2			model 3		
Comp. size	OD	95%CI	P value	OD	95%CI	P value	OD	95%CI	P value	
by July										
Large	Ref.			Ref.			Ref.			
Medium	0.93	0.82-1.05	0.229	0.98	0.86-1.10	0.691	1.06	0.94-1.21	0.330	
Small	0.77	0.69-0.87	<0.001	0.79	0.69-0.90	0.002	0.94	0.82-1.07	0.350	
Vaccination by comp.							1.56	1.40-1.74	<0.001	
by August										
Large	Ref.			Ref.			Ref.			
Medium	0.87	0.79-0.94	0.001	0.92	0.84-1.00	0.065	1.05	0.96-1.15	0.277	
Small	0.67	0.62-0.73	<0.001	0.76	0.69-0.83	<0.001	0.98	0.89-1.08	0.692	
Vaccination by comp.							1.98	1.83-2.15	<0.001	
by September										
Large	Ref.			Ref.			Ref.			
Medium	0.86	0.78-0.93	0.001	0.92	0.84-1.01	0.085	1.04	0.95-1.15	0.349	
Small	0.64	0.59-0.70	<0.001	0.77	0.70-0.84	<0.001	0.97	0.88-1.07	0.541	
Vaccination by comp.							1.90	1.76-2.07	<0.001	
by October										
Large	Ref.			Ref.			Ref.			
Medium	0.92	0.82-1.02	0.127	1.00	0.89-1.12	0.971	1.14	1.01-1.28	0.029	
Small	0.54	0.48-0.61	<0.001	0.75	0.67-0.84	<0.001	0.95	0.85-1.07	0.377	
Vaccination by comp.							2.05	1.84-2.27	<0.001	
by November										
Large	Ref.			Ref.			Ref.			
Medium	0.93	0.81-1.10	0.218	1.01	0.88-1.15	0.918	1.15	1.01-1.32	0.042	
Small	0.54	0.48-0.61	<0.001	0.73	0.64-0.83	<0.001	0.94	0.82-1.08	0.362	
Vaccination by comp.							2.14	1.88-2.43	<0.001	
by December										
Large	Ref.			Ref.			Ref.			
Medium	0.94	0.82-1.07	0.329	1.02	0.89-1.17	0.759	1.17	1.02-1.35	0.029	
Small	0.54	0.48-0.61	<0.001	0.73	0.64-0.83	<0.001	0.93	0.81-1.07	0.317	
Vaccination by comp.							2.14	1.83-2.15	<0.001	

442 model 1: adjusted for age and sex

443 model 2: model 1+ adjusted for annual household income, education, marital status, occupation and industry

444 model 3: model 2 + adjusted for company-arranged vaccination

445 Size of company: large (1-49); medium-sized (50-999); large (1000 or more)

446 Vaccination by comp.: vaccination arranged by company

447